Merck and Ariad in billion-dollar cancer drug pact
Merck and Ariad Pharmaceuticals have agreed to the terms of a potential billion-dollar global collaboration deal to develop and market Ariads cancer treatment known as AP23573.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.